Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

<p><b>Purpose:</b> Sodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine phosphatases, combined with IFN-alpha-2b (IFN-&#945;) inhibited solid tumor cell line growth <i>in vitro</i>. We conducted a phase I clinical trial with SSG plus IFN-&...

Full description

Bibliographic Details
Main Author: Aung Naing, James M. Reuben, Luis H. Camacho, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Claire Verschraegen, Saneese Stephen, Joann Aaron, David Hong, Jennifer Wheler, Razelle Kurzrock
Format: Article
Language:English
Published: Ivyspring International Publisher 2011-01-01
Series:Journal of Cancer
Online Access:http://www.jcancer.org/v02p0081.htm

Internet

http://www.jcancer.org/v02p0081.htm

Similar Items